Singapore-based venture capital firm Vickers Venture Partners has led the $13.2-million Series B funding in SiSaf, a UK-headquartered biotech startup that develops drugs using Bio-Courier technology, according to an announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
